Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Beauty Health (NASDAQ:SKIN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Insider and Institutional Ownership
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 93.3% of Beauty Health shares are owned by institutional investors. 8.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 41.0% of Beauty Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
Lucid Diagnostics has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Beauty Health has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 0 | 0 | 4 | 1 | 3.20 |
| Beauty Health | 1 | 3 | 1 | 0 | 2.00 |
Lucid Diagnostics presently has a consensus target price of $3.75, suggesting a potential upside of 141.94%. Beauty Health has a consensus target price of $2.50, suggesting a potential upside of 77.30%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, research analysts plainly believe Lucid Diagnostics is more favorable than Beauty Health.
Profitability
This table compares Lucid Diagnostics and Beauty Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -1,069.87% | N/A | -123.54% |
| Beauty Health | -8.11% | -44.83% | -3.54% |
Valuation & Earnings
This table compares Lucid Diagnostics and Beauty Health”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucid Diagnostics | $4.19 million | 21.96 | -$52.67 million | ($1.14) | -1.36 |
| Beauty Health | $334.29 million | 0.52 | -$100.12 million | ($0.43) | -3.28 |
Lucid Diagnostics has higher earnings, but lower revenue than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Lucid Diagnostics beats Beauty Health on 9 of the 15 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
